ArticleFrontiers in endocrinology2025
Role of B lymphocyte ratio in development of type 2 diabetes mellitus: results of a 7-year follow-up study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between B lymphocyte ratio (BLR) and type 2 diabetes mellitus (T2DM) outcome among healthy people. Methods: A retrospective study cohort was constructed based on healthy people who participated in annual physical examination in Shanghai Health and Medical Center from 2013 to 2020. For each patient, we collected data at the first physical examination in 2013. The Cox proportional risk regression model was used to analyze the association between BLR and the risk of T2DM. The mediating effect of traditional metabolic factors were further explored. Results: The study included 1505 participants with a mean age of 48.77 ± 8.33 years at baseline and a follow-up duration of 7.36 ± 0.99 years. During follow-up, a total of 72 new T2DM cases were identified (7.9/1000 person-years). After adjusted for confounders, the results showed that the participants with higher level of BLR (Quartile 4) had a doubling of the risk of T2DM when compared to those with lower BLR level (Quartile 1). The association of BLR with the risk of T2DM remained robust when patients with hypertension or patients with obesity were excluded. In addition, traditional metabolic factors including HDL-C and LDL-C partially mediated the association between BLR and the risk of T2DM. Conclusion: Elevated BLR level is significantly associated with a higher risk of T2DM development. HDL-C and LDL-C partially mediated the association between BLR and T2DM risk. Our research may have the potential to provide new therapeutic targets for the treatment of T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.